Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8878584 | 0.86 | KMT2A (0.68) | KMT2AMEN1GAATSHRPOLB | |
| SCHEMBL1260319 | 0.85 | KMT2A (0.66) | KMT2AMEN1GAATSHRPOLB | |
| SCHEMBL9848204 | 0.84 | KMT2A (0.64) | KMT2AMEN1GAATSHRPOLB | |
| SCHEMBL903110 | 0.83 | KMT2A (1.00) | KMT2AMEN1GAATSHRPOLB | |
| SCHEMBL4676533 | 0.82 | KMT2A (0.62) | KMT2AMEN1GAATSHRPOLB | |
| SCHEMBL316093 | 0.82 | KMT2A (0.76) | KMT2AMEN1GAATSHRPOLB | |
| SCHEMBL27722453 | 0.82 | KMT2A (0.76) | KMT2AMEN1GAATSHRPOLB | |
| SCHEMBL1930296 | 0.82 | MEN1 (0.70) | KMT2AMEN1GAATSHRPOLB | |
| Hydrochloric Acid SCHEMBL30684542 | 0.81 | KMT2A (0.97) | KMT2AMEN1GAATSHRPOLB | |
| Hydrochloric Acid SCHEMBL30684473 | 0.81 | KMT2A (0.97) | KMT2AMEN1GAATSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2019-09-10 | — | — | US | disclosed |
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | OHIO UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | OHIO UNIVERSITY (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | OHIO UNIVERSITY (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2016010610-A2 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | OHIO UNIVERSITY (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016010611-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | FABP1, LIPC, SLC10A1 | KMT2A 4190/4885MEN1 4206/4885GAA 202/4885 |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | KMT2A 4627/4885MEN1 1971/4885GAA 2160/4885 |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | FABP1, LIPC, SLC10A1 | KMT2A 4190/4885MEN1 4206/4885GAA 202/4885 |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | KMT2A 4617/4885MEN1 1988/4885GAA 2150/4885 |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | FGFR1, TYRO3, STAT6 | KMT2A 4554/4885MEN1 1937/4885GAA 2095/4885 |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | FGFR1, TYRO3, STAT6 | KMT2A 4554/4885MEN1 1937/4885GAA 2095/4885 |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | GSK3B, GSK3A, GSKIP | KMT2A 1687/4885MEN1 3068/4885GAA 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.